The Antibody Drug Conjugates (ADCs) Market has moved from niche oncology innovation to one of the most closely watched segments in biopharmaceutical development. Once considered technically complex and commercially uncertain, ADCs now represent a validated therapeutic platform with multiple regulatory approvals and an expanding clinical pipeline. In simple terms, ADCs combine the...